{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:06:39Z","timestamp":1778252799286,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation Project","award":["No. 82303673"],"award-info":[{"award-number":["No. 82303673"]}]},{"name":"National Natural Science Foundation Project","award":["No. 82073347"],"award-info":[{"award-number":["No. 82073347"]}]},{"name":"Chongqing Science and Health Joint Medical Research Project","award":["No. 2023GGXM002"],"award-info":[{"award-number":["No. 2023GGXM002"]}]},{"name":"Chongqing Talent Plan","award":["No. CQYC20210203119"],"award-info":[{"award-number":["No. CQYC20210203119"]}]},{"name":"Key Research and Development Program Project of Guangxi Zhuang Autonomous Region","award":["No. GuikeAB23026020"],"award-info":[{"award-number":["No. GuikeAB23026020"]}]},{"name":"Independent Project of Key Laboratory of Early Prevention & Treatment for Regional HighIncidence Tumor","award":["No. GKEZZ202230"],"award-info":[{"award-number":["No. GKEZZ202230"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03797-0","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T03:31:21Z","timestamp":1725593481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents"],"prefix":"10.1007","volume":"73","author":[{"given":"Dingyi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erha","family":"Munai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"3797_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","volume":"45","author":"S Peters","year":"2016","unstructured":"Peters S et al (2016) The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 45:139\u2013162. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.009","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3797_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/CCO.0b013e3283350106","volume":"22","author":"S Ricciardi","year":"2010","unstructured":"Ricciardi S, de Marinis F (2010) Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol 22(2):86\u201393. https:\/\/doi.org\/10.1097\/CCO.0b013e3283350106","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"3797_CR3","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","volume":"19","author":"SN Waqar","year":"2018","unstructured":"Waqar SN et al (2018) Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clin Lung Cancer 19(4):e373\u2013e379. https:\/\/doi.org\/10.1016\/j.cllc.2018.01.007","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"3797_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/jco.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA et al (2022) Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 40(5):492\u2013516. https:\/\/doi.org\/10.1200\/jco.21.02314","journal-title":"J Clin Oncol"},{"issue":"6","key":"3797_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","volume":"8","author":"AF Eichler","year":"2011","unstructured":"Eichler AF et al (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8(6):344\u2013356. https:\/\/doi.org\/10.1038\/nrclinonc.2011.58","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3797_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2174\/156800912799277511","volume":"12","author":"D Fortin","year":"2012","unstructured":"Fortin D (2012) The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets 12(3):247\u2013259. https:\/\/doi.org\/10.2174\/156800912799277511","journal-title":"Curr Cancer Drug Targets"},{"issue":"Suppl 3","key":"3797_CR7","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.21037\/tlcr.2019.05.15","volume":"8","author":"M Nishino","year":"2019","unstructured":"Nishino M, Soejima K, Mitsudomi T (2019) Brain metastases in oncogene-driven non-small cell lung cancer. Transl Lung Cancer Res 8(Suppl 3):S298\u2013S307. https:\/\/doi.org\/10.21037\/tlcr.2019.05.15","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"3797_CR8","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","volume":"16","author":"SF Powell","year":"2021","unstructured":"Powell SF et al (2021) Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol 16(11):1883\u20131892. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.020","journal-title":"J Thorac Oncol"},{"issue":"22","key":"3797_CR9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 378(22):2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"issue":"4","key":"3797_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/jco.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419\u2013425. https:\/\/doi.org\/10.1200\/jco.2011.38.0527","journal-title":"J Clin Oncol"},{"issue":"8","key":"3797_CR11","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1078-0432.Ccr-14-2082","volume":"21","author":"B Besse","year":"2015","unstructured":"Besse B et al (2015) Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized. Phase II Study Clin Cancer Res 21(8):1896\u20131903. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2082","journal-title":"Phase II Study Clin Cancer Res"},{"issue":"11","key":"3797_CR12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B et al (2018) Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol 4(11):1569\u20131575. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039","journal-title":"JAMA Oncol"},{"issue":"11","key":"3797_CR13","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA et al (2021) IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol 16(11):1909\u20131924. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.009","journal-title":"J Thorac Oncol"},{"key":"3797_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/annonc\/mdx091.010","volume":"28","author":"RS Herbst","year":"2017","unstructured":"Herbst RS et al (2017) Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. Ann Oncol 28:2","journal-title":"Ann Oncol"},{"key":"3797_CR15","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ijrobp.2014.08.206","volume":"90","author":"NA Rizvi","year":"2014","unstructured":"Rizvi NA et al (2014) Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy. Int J Radiat Oncol Biol Phys 90:S32\u2013S32. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.08.206","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3797_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.lungcan.2018.08.019","volume":"125","author":"SM Gadgeel","year":"2018","unstructured":"Gadgeel SM et al (2018) Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer 125:273\u2013281. https:\/\/doi.org\/10.1016\/j.lungcan.2018.08.019","journal-title":"Lung Cancer"},{"key":"3797_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctro.2022.04.013","volume":"35","author":"E Hart","year":"2022","unstructured":"Hart E et al (2022) Blood-brain barrier permeability following conventional photon radiotherapy - A systematic review and meta-analysis of clinical and preclinical studies. Clin Transl Radiat Oncol 35:44\u201355. https:\/\/doi.org\/10.1016\/j.ctro.2022.04.013","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"3797_CR18","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/ijc.34427","volume":"152","author":"Y Jin","year":"2023","unstructured":"Jin Y et al (2023) The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study. Int J Cancer 152(11):2351\u20132361. https:\/\/doi.org\/10.1002\/ijc.34427","journal-title":"Int J Cancer"},{"issue":"14","key":"3797_CR19","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/jco.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S et al (2020) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 38(14):1505\u20131517. https:\/\/doi.org\/10.1200\/jco.19.03136","journal-title":"J Clin Oncol"},{"key":"3797_CR20","doi-asserted-by":"publisher","first-page":"1059995","DOI":"10.3389\/fimmu.2022.1059995","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S et al (2022) PD-1\/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1\/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. Front Immunol 13:1059995. https:\/\/doi.org\/10.3389\/fimmu.2022.1059995","journal-title":"Front Immunol"},{"issue":"1","key":"3797_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40164-023-00412-3","volume":"12","author":"H Wang","year":"2023","unstructured":"Wang H et al (2023) Outcome differences between PD-1\/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases. Exp Hematol Oncol 12(1):56. https:\/\/doi.org\/10.1186\/s40164-023-00412-3","journal-title":"Exp Hematol Oncol"},{"issue":"10066","key":"3797_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(16)32517-x","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255\u2013265. https:\/\/doi.org\/10.1016\/s0140-6736(16)32517-x","journal-title":"Lancet"},{"issue":"21","key":"3797_CR23","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L et al (2018) Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 379(21):2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"issue":"1","key":"3797_CR24","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","volume":"11","author":"Y Ye","year":"2020","unstructured":"Ye Y et al (2020) Sex-associated molecular differences for cancer immunotherapy. Nat Commun 11(1):1779. https:\/\/doi.org\/10.1038\/s41467-020-15679-x","journal-title":"Nat Commun"},{"issue":"8","key":"3797_CR25","doi-asserted-by":"publisher","first-page":"9760","DOI":"10.1002\/cam4.5696","volume":"12","author":"M Sato","year":"2023","unstructured":"Sato M et al (2023) Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy. Cancer Med 12(8):9760\u20139773. https:\/\/doi.org\/10.1002\/cam4.5696","journal-title":"Cancer Med"},{"key":"3797_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670313","volume":"11","author":"L Fang","year":"2021","unstructured":"Fang L et al (2021) Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer. Front Oncol 11:670313. https:\/\/doi.org\/10.3389\/fonc.2021.670313","journal-title":"Front Oncol"},{"issue":"1","key":"3797_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M et al (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18(1):60. https:\/\/doi.org\/10.1186\/s12943-019-0974-6","journal-title":"Mol Cancer"},{"issue":"12","key":"3797_CR28","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","volume":"69","author":"Y Yang","year":"2020","unstructured":"Yang Y et al (2020) Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother 69(12):2523\u20132532. https:\/\/doi.org\/10.1007\/s00262-020-02641-5","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"3797_CR29","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2159-8290.Cd-21-0976","volume":"12","author":"MR Strickland","year":"2022","unstructured":"Strickland MR et al (2022) Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity. Cancer Discov 12(5):1199\u20131216. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0976","journal-title":"Cancer Discov"},{"issue":"1","key":"3797_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z et al (2022) Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 7(1):258. https:\/\/doi.org\/10.1038\/s41392-022-01102-y","journal-title":"Signal Transduct Target Ther"},{"key":"3797_CR31","doi-asserted-by":"publisher","first-page":"1200941","DOI":"10.3389\/fimmu.2023.1200941","volume":"14","author":"A Shafqat","year":"2023","unstructured":"Shafqat A et al (2023) Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy. Front Immunol 14:1200941. https:\/\/doi.org\/10.3389\/fimmu.2023.1200941","journal-title":"Front Immunol"},{"issue":"10","key":"3797_CR32","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.21037\/tcr-20-902","volume":"9","author":"Q He","year":"2020","unstructured":"He Q, Zhang C, Tang S, Li J, Ren Q (2020) Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis. Transl Cancer Res. 9(10):5909\u20135924. https:\/\/doi.org\/10.21037\/tcr-20-902","journal-title":"Transl Cancer Res."}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03797-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03797-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:04:35Z","timestamp":1729785875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03797-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03797-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research involving human participants was reviewed and approved by the ethics committees of Chongqing University Cancer Hospital and Guangxi Medical University Cancer Hospital. Patients\/participants provided written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"226"}}